EURONEXT |
Date/Time | / |
Chg. / Chg.(%) | - / |
Bid | - |
Ask | - |
Open | - |
Previous Close | - |
High | - |
Low | - |
Volume [EUR] | - |
Volume [Units] | |
Price fixings | |
ISIN | NL0006294274 |
Security | ENX |
Exchange | Euronext - Paris |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Euronext - P.. | 91.95 | ![]() |
6,948 |
Cboe Europe .. | 92.00 | ![]() |
1,001 |
Turquoise | 92.20 | ![]() |
98 |
London Inter.. | 92.00 | ![]() |
74 |
Düsseldorf | 91.05 | ![]() |
0 |
Frankfurt | 88.7000 | ![]() |
0 |
München | 91.50 | ![]() |
0 |
Berlin | 92.15 | ![]() |
0 |
Vienna Globa.. | 92.10 | ![]() |
0 |
gettex | 92.350 | ![]() |
|
Stuttgart | 91.150 | ![]() |
|
Lang & Schwa.. | 91.80 | ![]() |
|
Cboe Europe .. | 90.50 | 898 | |
TradeGate | 90.60 | 430 | |
Cboe Europe .. | 90.35 | 24 | |
Nasdaq Other.. | 114.5000 | 107 | |
Euronext - L.. | 38.820 |
News
- AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19
08:26 - GlobeNewswire - AB Science annonce qu'une nouvelle publication indépendante confirme que le masitinib a une activité anti-virale contre le virus SARS-CoV-2 in vitro et est un candidat prometteur pour le traitement du Covid-19
08:26 - GlobeNewswire - Stellantis convenes EGM to approve distribution of Faurecia shares and cash
08:00 - GlobeNewswire - Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
01/20/2021 / 08:00 - GlobeNewswire - Kiadis draws €20 million from bridge loan with Sanofi
01/14/2021 / 07:00 - GlobeNewswire